Co-PSMA data presented
Filed with ASX · · 6 pages · English
Summary by 6ix AI
Clarity Pharmaceuticals Ltd. announced the presentation of Co-PSMA trial data at the EAU Annual Congress, with the findings accepted for publication in the European Urology journal. The study's results indicated a higher true positive rate and a substantial impact on patient management decisions.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Clarity Pharmaceuticals Ltd. on 6ix
Earlier from Clarity Pharmaceuticals
- Registrational Phase III AMPLIFY trial: Target number of participants achieved
- AMPLIFY trial - Target number of participants achieved
- Half Yearly Report and Accounts
- SECuRE trial update: Another participant with undetectable PSA & negative PSMA PET
- SECuRE trial update
Later from Clarity Pharmaceuticals
- Co-PSMA data presented at EAU Annual Congress 2026 with manuscript accepted for publication in the European Urology journal
- Clarity signs a large-scale Manufacturing Supply Agreement
- Clarity signs a large-scale Manufacturing Supply Agreement for copper-64 with Theragenics
- Co-PSMA data published in the European Urology journal
- Clarity signs a Commercial Manufacturing Agreement
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals